Emerging treatments like rusfertide may reduce phlebotomies and improve life for patients with polycythemia vera, according ...

Ionis ended Q1 with $2.1 billion in cash, cash equivalents, and short-term investments. The company’s long-term debt is made up of convertible senior notes and totals approximately $1.4 billion.

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

Across the recent three months, 10 analysts have shared their insights on Ionis Pharmaceuticals IONS, expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll ...

Fintel reports that on July 1, 2025, Barclays upgraded their outlook for Ionis Pharmaceuticals (NasdaqGS:IONS) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 47.25% Upside As of ...

Ionis Pharmaceuticals (IONS) shares ended the last trading session 9.1% higher at $43.59. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a biotechnology company with a market capitalization of $6.84 billion focused on developing treatments for rare diseases, has been making significant ...

All You Need to Know About Ionis Pharmaceuticals Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs.

The dystopian “Vera, or Faith” explores how a 10-year-old girl’s family experiences democracy’s slide into fascism.

She’s as stylish as ever. Over the weekend, fashion designer Vera Wang celebrated her 76th birthday in Paris, flashing a hint of thigh in a unique black dress.

A precocious 10-year-old straight out of a New Yorker cartoon grapples with status and a fracturing family in Gary Shteyngart's 'Vera, or Faith.' ...